Login error for Eduroam and Ephorte - see the operational notice

WP2

Radionuclide targeted therapy and imaging in Glioblastoma

The plasticity of GB tumor cells and their ability to infiltrate adjoining brain tissue limits the effectiveness of current cancer therapies. Microglia plays an important role in GB progression. Inhibition of EGFR and CSF-1R decreases microglia-stimulated invasion of GB cells. Specific radiopharmaceuticals targeting EGFR or CSF-1R will be developed (WP3/Bergen) and applied as (i) diagnostic tool (11C, 18F) and (ii) radionuclide targeted therapy with radiometals (radiotherapeutics) combined with chemo- and external radiotherapy. To evaluate its EGFR or CSF-1R affinity and selectivity, radiopharmaceuticals will be tested by in vivo PET/SPECT/MR in healthy animals and orthotopic animals models of GB (UNN).


Project Staff

 

Marcel Lindemann

Researcher (Postdoctoral Fellow)
Department of Clinical Medicine

Yngve Guttormsen

Research Fellow (PhD Candidate)
Department of Clinical Medicine

Collaboration Partners

Researcher/Group
Andreas Tue Ingemann Jensen
Olaug Hjelstuen
Sindre Hassfjell
Jason Cai

Affiliation
Technical University of Denmark (DTU) Nutech, Denmark
Institute for Energy Technology (IFE), Norway
Institute for Energy Technology (IFE), Norway
Yale University, USA

 

 


 

 

Share:

Principal Investigators



Mathias Kranz, PhD

Researcher
University Hospital of North Norway (UNN)


Rune Sundset
Assoc. Prof., MD, PhD